SCHEMBL807768

SCHEMBL807768

COc1ccc(/C=C/[N+](=O)[O-])cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 5/20 1.00
ALDH1A1 P00352 4/20 0.74
MAPK1 P28482 3/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
SYK P43405 2/20 0.74
EGFR P00533 2/20 0.74
LMNA P02545 2/20 0.74
MAPT P10636 2/20 0.74
GALR2 O43603 1/20 0.74
HTT P42858 1/20 0.74
NPSR1 Q6W5P4 1/20 0.74
CYP19A1 P11511 2/20 0.67
PTGS2 P35354 1/20 0.67
KMT2A Q03164 1/20 0.62
FBP1 P09467 4/20 0.62
ABL1 P00519 1/20 0.61
ABL2 P42684 1/20 0.61
HSP90AA1 P07900 2/20 0.58
AGTR1 P30556 1/20 0.58
KDM4E B2RXH2 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29727003 1.00 VCP (1.00) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL793160 1.00 VCP (1.00) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL28863042 0.98 VCP (0.97) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL4146797 0.89 VCP (0.79) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL1158756 0.88 VCP (0.78) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL1158758 0.88 VCP (0.78) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL2742572 0.88 VCP (0.78) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL7207216 0.88 VCP (0.78) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL1411603 0.88 VCP (0.78) VCPALDH1A1MAPK1SMN1; SMN2SYK
SCHEMBL3100101 0.87 VCP (0.77) VCPALDH1A1MAPK1SMN1; SMN2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US claimed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 WO claimed
WO-2026105118-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-05-21 WO disclosed
EP-4616906-A2 BENZO[A]PHENANTHRIDINE DERIVATIVES AS YAP/TAZ INHIBITORS Sanford Burnham Prebys Medical Discovery Institute (US) 2025-09-17 EP disclosed
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US disclosed
EP-4326227-A1 STABILIZED FORMULATIONS ModernaTX, Inc. (US) 2024-02-28 EP disclosed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 WO disclosed
US-20220370616-A1 STABILIZED FORMULATIONS ARES CAPITAL CORPORATION, AS AGENT 2022-11-24 US disclosed
WO-2022226277-A1 STABILIZED FORMULATIONS MODERNATX, INC. (US) 2022-10-27 WO disclosed
US-20220267277-A1 DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2022-08-25 US disclosed
CN-110511147-A A kind of restoring method of nitroolefin WUHAN JARNORKING PHARMACEUTICAL TECH CO LTD 2019-11-29 CN disclosed
US-4613606-A CARDIOVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1986-09-23 US disclosed
US-4569941-A Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal USV PHARMACEUTICAL CORP. (US) 1986-02-11 US disclosed
EP-0050370-B1 SUBSTITUTED CYCLIC AMINES USV PHARMACEUTICAL CORPORATION (US) 1985-08-28 EP disclosed
US-4342692-A USEFUL AS CARDIOTONIC AGENTS, ANTIHYPERTENSIVE AGENTS, AND ANTIALL USV PHARMACEUTICAL CORPORATION (US) 1982-08-03 US disclosed
EP-0050370-A1 Substituted cyclic amines USV PHARMACEUTICAL CORPORATION (US) 1982-04-28 EP disclosed
US-4148795-A Dithiocarbamate ester bactericides and fungicides AMERICAN CYANAMID COMPANY (US) 1979-04-10 US disclosed
US-4038288-A DITHIOCARBAMATE ESTER BACTERICIDES AND FUNGICIDES AMERICAN CYANAMID COMPANY (US) 1977-07-26 US disclosed
US-4011230-A DITHIOCARBAMATE ESTER BACTERICIDES AND FUNGICIDES AMERICAN CYANAMID COMPANY (US) 1977-03-08 US disclosed
US-3989714-A ANTIVIRAL WARNER-LAMBERT COMPANY (US) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267277-A1 DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE PRLHR, YAP1, MST1R VCP 3545/4885ALDH1A1 1281/4885MAPK1 1277/4885
US-20220370616-A1 STABILIZED FORMULATIONS RNMT, NSUN2, POLN VCP 1388/4885ALDH1A1 1906/4885MAPK1 4647/4885
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE IL15, IL2, IL17A VCP 4541/4885ALDH1A1 3528/4885MAPK1 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.